Partnering with a Trusted EU-GMP Formulary Provider
Cannamedical Britannia is entering the UK market as the British arm of Cannamedical Pharma GmbH, one of Europe’s leading pharmaceutical-grade medical cannabis companies. We support over 120,000 patients across Europe, working with more than 1,100 pharmacy partners and 30+ EU-GMP certified cultivators.
Our EU-GMP Portfolio
Every product in the Cannamedical formulary is manufactured under EU Good Manufacturing Practice (EU-GMP) standards — the same regulatory framework applied to all prescription pharmaceuticals in Europe. This means your patients receive consistent, analytically verified cannabis flower and extracts with documented cannabinoid profiles, terpene data, microbiological test results, and full chain-of-custody traceability from cultivator to patient.
Our portfolio includes a broad range of chemovars across THC-dominant, CBD-dominant and balanced profiles, allowing you to tailor therapeutic recommendations to individual patient needs and eligibility criteria.
Clinical Support
We understand that prescribing medical cannabis in the UK involves navigating a complex regulatory landscape. Cannamedical Britannia provides clinical partnership support including:
- Product formulary access with full analytical documentation
- Patient eligibility support resources
- Clinical education on cannabinoid pharmacology and therapeutic applications
- Dedicated UK medical liaison contact
- Regular updates on MHRA guidance and UK clinical evidence
Partnership Benefits
Clinicians and specialist consultants registered with the GMC who prescribe medical cannabis can apply to access our UK formulary. We offer:
- Direct line to a UK-based medical affairs contact
- Access to our complete EU-GMP product portfolio with COA documentation
- Pharmacy referral network for Schedule 2 dispensing
- Ongoing clinical data on patient outcomes from our European network
Who Can Prescribe Medical Cannabis in the UK?
Medical cannabis may be prescribed by specialist medical consultants registered with the GMC. It is not available on the NHS for most conditions and is typically accessed through specialist private clinics. As a prescribing clinician, you are the gateway to improved patient outcomes for those who have exhausted conventional treatment pathways.
Get in Touch
We are actively building our UK clinical network ahead of product launch in 2026/2027. If you are a prescribing specialist or clinic director interested in learning more about Cannamedical Britannia’s formulary and partnership structure, please contact us directly.
Clinical Partnerships: uk@cannamedical.com
You can also review our EU-GMP quality standards or explore the full product portfolio.
